

# Peter J Greasley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3606838/publications.pdf>

Version: 2024-02-01

13  
papers

572  
citations

1306789

7  
h-index

1125271

13  
g-index

13  
all docs

13  
docs citations

13  
times ranked

998  
citing authors

#	ARTICLE	IF	CITATIONS
1	Predicted Cardiac Functional Responses to Renal Actions of SGLT2i in the DAPACARD Trial Population: A Mathematical Modeling Analysis. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 541-554.	1.0	2
2	Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from <scp>DAPASALT</scp> and <scp>DIAMOND</scp>. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1578-1587.	2.2	11
3	Bilirubin levels and kidney function decline: An analysis of clinical trial and real world data. <i>PLoS ONE</i> , 2022, 17, e0269970.	1.1	2
4	Focal Segmental Glomerulosclerosis, Risk Factors for End Stage Kidney Disease, and Response to Immunosuppression. <i>Kidney360</i> , 2021, 2, 105-113.	0.9	10
5	Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPAâ€CHF Study Population: A Mathematical Modeling Analysis. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 636-648.	1.0	9
6	Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 76-91.	1.3	8
7	Identification of Proteins Associated with the Early Restoration of Insulin Sensitivity After Biliopancreatic Diversion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4157-e4168.	1.8	4
8	Development of Human Target Validation Classification that Predicts Future Clinical Efficacy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 368, 255-261.	1.3	1
9	The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 339-346.	0.4	28
10	Why do <scp>SGLT2</scp> inhibitors reduce heart failure hospitalization? <scp>A</scp> differential volume regulation hypothesis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 479-487.	2.2	336
11	Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	91
12	Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, F1295-F1306.	1.3	46
13	Deletion of Cpr55 Results in Subtle Effects on Energy Metabolism, Motor Activity and Thermal Pain Sensation. <i>PLoS ONE</i> , 2016, 11, e0167965.	1.1	24